The effects of empagliflozin on measured glomerular filtration rate and estimated extracellular and plasma volumes in patients with type 2 diabetes.
Mikkel JürgensMorten SchouPhilip HasbakAndreas KjaerEmil WolskBo ZerahnNiels Høegh Brandt-JacobsenPeter Haulund GaedeEllen BurgessJens FaberSilvio E InzucchiFinn GustafssonCaroline KistorpPublished in: Diabetes, obesity & metabolism (2023)
Treatment with empagliflozin for 13 weeks reduced mGFR, estimated ECV and estimated PV in patients with T2D and high risk of cardiovascular events.